Industry
Biotechnology
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Loading...
Open
5.77
Mkt cap
330M
Volume
159K
High
5.93
P/E Ratio
-6.62
52-wk high
6.91
Low
5.32
Div yield
N/A
52-wk low
1.96
Portfolio Pulse from Happy Mohamed
March 19, 2024 | 8:01 pm
Portfolio Pulse from Benzinga Insights
March 19, 2024 | 10:06 am
Portfolio Pulse from Benzinga Insights
March 18, 2024 | 2:01 pm
Portfolio Pulse from Benzinga Insights
February 09, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
November 14, 2023 | 4:52 pm
Portfolio Pulse from Benzinga Newsdesk
November 13, 2023 | 10:16 pm
Portfolio Pulse from Vandana Singh
August 15, 2023 | 7:32 pm
Portfolio Pulse from Lisa Levin
August 15, 2023 | 7:04 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.